melanoma

Esmo 2020 – can Alkermes succeed where Nektar failed?
Esmo 2020 – can Alkermes succeed where Nektar failed?
EP Vantage
Alkermes
ESMO
ALKS 4230
melanoma
Flag link:
OnKure, Pfizer collaborate to evaluate combination of OKI-179 and binimetinib
OnKure, Pfizer collaborate to evaluate combination of OKI-179 and binimetinib
Pharmaceutical Business Review
OnKure
Pfizer
OKI-179
melanoma
Flag link:
Highlight Therapeutics trials second-line melanoma combo after immunotherapy fails
Highlight Therapeutics trials second-line melanoma combo after immunotherapy fails
Pharmaforum
Highlight Therapeutics
melanoma
BO-112
Keytruda
Merck
Flag link:
FDA approves Roche’s Tecentriq plus Cotellic and Zelboraf for people with advanced melanoma
FDA approves Roche’s Tecentriq plus Cotellic and Zelboraf for people with advanced melanoma
Pharmaceutical Business Review
Roche
FDA
Tecentriq
Cotellic
Zelboraf
melanoma
Flag link:
Regeneron pairs with BioNTech on melanoma immunotherapy
Regeneron pairs with BioNTech on melanoma immunotherapy
Pharmaforum
Regeneron
BioNTech
melanoma
Libtayo
vaccines
BNT111
MRNA
Flag link:
Roche’s Tecentriq claims melanoma OK, but don’t expect a sales surge
Roche’s Tecentriq claims melanoma OK, but don’t expect a sales surge
Pharmaforum
Roche
Tecentriq
FDA
melanoma
Bristol-Myers Squibb
Merck
Flag link:
AACR: Roche's Tecentriq, added to Cotellic and Zelboraf, stalls melanoma progression
AACR: Roche's Tecentriq, added to Cotellic and Zelboraf, stalls melanoma progression
Fierce Pharma
Roche
Tecentriq
Cotellic
Zelboraf
melanoma
AACR
Flag link:
Elios Therapeutics presents new Phase IIb data for personalized cancer vaccine in high-risk melanoma patients
Elios Therapeutics presents new Phase IIb data for personalized cancer vaccine in high-risk melanoma patients
Pharmaceutical Business Review
Elios Therapeutics
clinical trials
vaccines
melanoma
Flag link:
Immuno-oncology combination for melanoma using Nektar drug boosts cell therapy in mice
Immuno-oncology combination for melanoma using Nektar drug boosts cell therapy in mice
Fierce Biotech
melanoma
Nektar Therapeutics
bempegaldesleukin
Flag link:
Nektar shows durability of Opdivo combo in 18-month update
Nektar shows durability of Opdivo combo in 18-month update
Fierce Biotech
Nektar Therapeutics
NKTR-214
Opdivo
Bristol-Myers Squibb
melanoma
clinical trials
Flag link:
Led by BioNTech, six biotechs line up for October IPOs
Led by BioNTech, six biotechs line up for October IPOs
Endpoints
IPOs
MRNA
melanoma
inebilizumab
NMOSD
blood cancer
solid tumors
BioNTech
ADC Therapeutics
Viela Bio
Frequency Therapeutics
Aprea Therapeutics
Monopar Therapeutics
Flag link:
Skin Cancer Diagnostics Company Files for $57 Million IPO
Skin Cancer Diagnostics Company Files for $57 Million IPO
CP Wire
Castle Biosciences
melanoma
IPOs
diagnostics
Flag link:
Skin Cancer Diagnostics Company Files for $57 Million IPO
Castle Biosciences
melanoma
IPOs
diagnostics
Flag link:
Complete response rate in Nektar melanoma trial hits 34%
Complete response rate in Nektar melanoma trial hits 34%
Fierce Biotech
Nektar
NKTR-214
Opdivo
ASCO 2019
melanoma
Flag link:
Keytruda gets okay from FDA for adjuvant melanoma
Keytruda gets okay from FDA for adjuvant melanoma
Pharmaforum
FDA
Merck
adjuvant melanoma
melanoma
Keytruda
Flag link:
The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials
The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials
Yahoo/Benzinga
Motif Biosciences
Iclaprim
Merck
Keytruda
melanoma
JNJ
esketamine
ASCO
Pfizer
Veru. earnings
Aveo Pharmaceuticals
Calithera Biosciences
Flag link:
Down but Not Out: 10 Biggest Drug Trials That Saw Challenges in 2018
Down but Not Out: 10 Biggest Drug Trials That Saw Challenges in 2018
BioSpace
clinical trials
Takeda
Zinfandel Pharmaceuticals
pioglitazone
Alzheimer's disease
Boehringer Ingelheim
BI 409306
Merck
verubecestat
Celgene
MS
ozanimod
Incyte
ID01
melanoma
vTv Therapeutics
azeliragon
Roche
Tecentriq
Exelixis
colorectal cancer
JNJ
atabacestat
Sareptat Therapeutics
DMD
Exondys 51
Alkermes
ALKS-5461
clinical depression
Flag link:
Merck bags adjuvant okay for Keytruda in melanoma
Merck bags adjuvant okay for Keytruda in melanoma
Pharmaforum
Merck
Europe
Keytruda
melanoma
Flag link:
OncoSec’s defense of weak preliminary Tavo data for PD-1 resistant melanoma can’t stop a rout
OncoSec’s defense of weak preliminary Tavo data for PD-1 resistant melanoma can’t stop a rout
Endpoints
OncoSec
Merck
Keytruda
Tavo
melanoma
Flag link:
Immunotherapy Drugs Slow Skin Cancer That Has Spread to the Brain
Immunotherapy Drugs Slow Skin Cancer That Has Spread to the Brain
New York Times, NY
melanoma
Opdivo
clinical trials
Bristol-Myers Squibb
Flag link:

Pages